Antioxidant-Free Bendamustine Injection for Liquid Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bendamustine hydrochloride solutions are prone to rapid hydrolytic, photolytic, and oxidative degradation, necessitating complex lyophilization processes and the use of antioxidants that can cause adverse reactions in patients, and there is a need for stable, ready-to-use or ready-to-dilute formulations with enhanced stability and reduced impurities.
Innovation Solution
Development of antioxidant-free, stable liquid injectable compositions using non-aqueous solvents like polyethylene glycol and dehydrated alcohol, with controlled oxygen levels and pH adjustment, eliminating the need for inert gas purging and ensuring long-term stability and reduced impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If lyophilization process is used to prevent hydrolytic degradation, then stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by using non-aqueous solvents (polyethylene glycol and dehydrated alcohol) instead of aqueous solutions, and by controlling pH and oxygen levels. This parameter change allows the drug to be formulated as a stable liquid solution without requiring lyophilization, thereby maintaining stability while simplifying manufacturing.
2Stability of the object's composition
If antioxidants are added to prevent oxidative degradation, then stability is improved, but adverse reactions increase
Solution Approach 1:
The patent extracts and eliminates antioxidants from the formulation by using a non-aqueous solvent system (polyethylene glycol and dehydrated alcohol) that inherently prevents oxidative degradation of bendamustine. The controlled oxygen levels and non-aqueous environment remove the need for antioxidants, thereby maintaining stability while avoiding adverse reactions associated with antioxidant additives.
3Ease of operation
If ready-to-use liquid composition is developed, then ease of operation is improved, but stability deteriorates
Solution Approach 1:
The patent changes the formulation parameters by using non-aqueous solvents (polyethylene glycol and dehydrated alcohol) and controlling pH and oxygen levels, which enables the development of ready-to-use liquid compositions that maintain long-term stability without requiring lyophilization or reconstitution, thereby achieving both ease of use and stability.
4Ease of manufacture
If non-aqueous solvent system is used, then manufacturing simplicity is improved, but solubility may be affected
Solution Approach 1:
The patent uses a composite solvent system comprising polyethylene glycol and dehydrated alcohol in specific ratios. This composite material combines the advantages of both solvents: polyethylene glycol provides good solubility for bendamustine and stabilizes the drug, while dehydrated alcohol enhances solubility and maintains the liquid state. The composite solvent system achieves both manufacturing simplicity and adequate solubility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions maintain stability for at least 6 months at 2-8°C with reduced impurities, minimizing infusion-related adverse events and simplifying administration by being ready-to-use or ready-to-dilute, suitable for intravenous administration.
Implementation Method 1
stable liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof... using non-aqueous solvents like polyethylene glycol and dehydrated alcohol
Implementation Method 2
Bendamustine also undergoes photolytic and oxidative degradation... Development of antioxidant-free, stable liquid injectable compositions... with controlled oxygen levels
Implementation Method 3
The compositions maintain stability for at least 6 months at 2-8°C
Data Source
AI summary
Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.